The effect of silver fibre gloves on Raynaud's phenomenon in patients with systemic sclerosis: a double-blind randomized crossover trial

被引:3
|
作者
Liem, Sophie I. E. [1 ]
Hoekstra, Eva M. [1 ]
Bonte-Mineur, Femke [2 ]
Checa, Cesar Magro [3 ]
Schouffoer, Anne [4 ]
Allaart, Cornelia F. [1 ]
Huizinga, Tom W. J. [1 ]
Bergstra, Sytske Anne [1 ]
de Vries-Bouwstra, Jeska K. [1 ]
机构
[1] Leiden Univ, Dept Rheumatol, Med Ctr, POB 9600, NL-2300 RC Leiden, Netherlands
[2] Maasstad Ziekenhuis, Dept Rheumatol & Clin Immunol, Rotterdam, Netherlands
[3] Zuyderland Med Ctr, Dept Rheumatol, Heerlen, Netherlands
[4] Haga Ziekenhuis, Dept Rheumatol, The Hague, Netherlands
关键词
SSc; scleroderma; RP; silver fibre gloves; crossover trial; MINIMALLY IMPORTANT DIFFERENCE; QUALITY-OF-LIFE; SCLERODERMA; MANAGEMENT;
D O I
10.1093/rheumatology/keac243
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. Silver fibre gloves transport heat from the palm to the fingers, possibly reducing the burden of RP in SSc patients. We aim to evaluate the clinical efficiency of this intervention. Methods. A multicentre, double-blind, randomized trial was performed, accounting for interindividual differences and external factors using a crossover design. Patients were randomized in two groups: group 1 wore 8% silver fibre gloves in period 1 and normal gloves in period 2 and group 2 vice versa. Each period lasted 6 weeks. The primary outcome was the Raynaud Condition Score (RCS) over time (minimal clinical important difference 1.4), assessed three times per week using an online questionnaire. Secondary outcomes included vascular complications and Scleroderma-Health Assessment Questionnaire (SHAQ). Outcomes were evaluated before unblinding using linear mixed models. Results. A total of 85 SSc patients were included, with 76 completing the study. The mean RCS during 2 weeks before the study (i.e. without gloves) was 6.4 (s.D. 1.6). Both with silver fibre gloves and normal gloves the mean RCS decreased to 3.9 (s.D. 2.3) with a similar course over time. There was no difference in mean RCS over time between the type of gloves [beta=0.067 (95% CI -0.006, 0.19)]. Of secondary outcomes, total SHAQ [beta=0.036 (95% CI 0.026, 0.046)] was slightly higher with silver fibre gloves, which is clinically irrelevant. Three patients developed new digital ulcers with normal gloves vs one patient with silver fibre gloves [odds ratio 3.2 (95% CI 0.32, 31.1)]. Conclusions. Wearing gloves in SSc patients clearly decreases the RP burden. Our results do not support the hypothesis that increased heat transport of 8% silver fibre gloves is associated with less disease burden as measured in this study by the RCS compared with normal gloves.
引用
收藏
页码:SI74 / SI81
页数:8
相关论文
共 50 条
  • [1] THE EFFECT OF SILVER FIBER GLOVES ON RAYNAUD'S PHENOMENON IN PATIENTS WITH SYSTEMIC SCLEROSIS: A DOUBLE-BLIND RANDOMIZED CROSS-OVER TRIAL.
    Liem, S.
    Hoekstra, E.
    Bonte-Mineur, F.
    Checa, C. Magro
    Schouffoer, A.
    Allaart, C.
    Huizinga, T.
    Bergstra, S. A.
    De Vries-Bouwstra, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 726 - 727
  • [2] A RANDOMIZED DOUBLE-BLIND CROSSOVER TRIAL OF NIFEDIPINE IN THE TREATMENT OF PRIMARY RAYNAUD PHENOMENON
    CORBIN, DOC
    WOOD, DA
    MACINTYRE, CCA
    HOUSLEY, E
    CLINICAL SCIENCE, 1985, 69 : P21 - P21
  • [3] Effect Of Aminaftone On Raynaud's Phenomenon Secondary To Systemic Sclerosis: A Double-Blind Prospective, Randomized, Placebo-Controlled Pilot Study
    Santaniello, Alessandro
    Vigone, Barbara
    Caronni, Monica
    Beretta, Lorenzo
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S300 - S300
  • [4] Use of Heated Gloves for Raynaud's Phenomenon in Systemic Sclerosis
    Kumar, Kimti
    Matardiah, Nor Hashimah Abu Mansor
    Griggs, Kim
    Kunnel, Aline
    Walker, Jennifer
    Proudman, Susanna
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 1245 - 1247
  • [5] Randomized Placebo-Controlled Crossover Trial of Tadalafil in Raynaud's Phenomenon Secondary to Systemic Sclerosis
    Schiopu, Elena
    Hsu, Vivien M.
    Impens, Ann J.
    Rothman, Jennifer A.
    McCloskey, Deborah A.
    Wilson, Julianne E.
    Phillips, Kristine
    Seibold, James R.
    JOURNAL OF RHEUMATOLOGY, 2009, 36 (10) : 2264 - 2268
  • [6] A DOUBLE-BLIND CROSSOVER STUDY OF NIFEDIPINE-RETARD IN PATIENTS WITH RAYNAUD PHENOMENON
    FINCH, MB
    COPELAND, S
    PASSMORE, AP
    JOHNSTON, GD
    CLINICAL RHEUMATOLOGY, 1988, 7 (03) : 359 - 365
  • [7] Oral N-acetylcysteine in the treatment of Raynaud's phenomenon secondary to systemic sclerosis: a randomized, double-blind, placebo-controlled clinical trial
    Uchoa Correa, Marcelo Jose
    Mariz, Henrique Ataide
    Coelho Andrade, Luis Eduardo
    Kayser, Cristiane
    REVISTA BRASILEIRA DE REUMATOLOGIA, 2014, 54 (06) : 452 - 458
  • [8] ORAL N-ACETYLCYSTEINE IN THE TREATMENT OF RAYNAUD'S PHENOMENON SECONDARY TO SYSTEMIC SCLEROSIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL
    Kayser, C.
    Correa, M. J. U.
    Mariz, H. A.
    Andrade, L. E. C.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (02) : S94 - S94
  • [9] A DOUBLE-BLIND TRIAL OF DILTIAZEM IN THE TREATMENT OF RAYNAUD PHENOMENON
    WHITE, CJ
    ABRAHAMS, LA
    OVERTONKEARY, P
    SINGLETON, PJ
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1986, 7 (02) : A177 - A177
  • [10] Vardenafil for the Treatment of Raynaud Phenomenon: A Randomized, Double-blind, Placebo-Controlled Crossover Study
    Caglayan, Evren
    Axmann, Sarah
    Hellmich, Martin
    Moinzadeh, Pia
    Rosenkranz, Stephan
    ARCHIVES OF INTERNAL MEDICINE, 2012, 172 (15) : 1182 - 1184